MITCHELL, WILLIAM JOHN THOMAS
 Distribuzione geografica
Continente #
AS - Asia 147
NA - Nord America 77
EU - Europa 55
OC - Oceania 14
AF - Africa 1
Totale 294
Nazione #
US - Stati Uniti d'America 77
TW - Taiwan 40
CN - Cina 31
IN - India 16
AU - Australia 14
IT - Italia 13
JP - Giappone 13
SG - Singapore 13
CH - Svizzera 11
KR - Corea 11
FR - Francia 6
IE - Irlanda 6
PH - Filippine 6
DE - Germania 4
GB - Regno Unito 4
SE - Svezia 4
VN - Vietnam 4
HK - Hong Kong 3
ID - Indonesia 3
FI - Finlandia 2
GR - Grecia 2
NP - Nepal 2
TR - Turchia 2
EG - Egitto 1
IR - Iran 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
PT - Portogallo 1
RO - Romania 1
RU - Federazione Russa 1
Totale 294
Città #
Hsinchu 17
Sydney 14
Geneva 11
Handayama 10
Santa Clara 10
Singapore 10
Taipei 9
Los Angeles 6
Manila 6
Shanghai 6
Turin 6
Eunpyeong-gu 4
Anstaing 3
Boston 3
Cincinnati 3
Columbus 3
Dublin 3
Fairfield 3
Hyderabad 3
Jakarta 3
Jamshedpur 3
Kolkata 3
Mumbai 3
New York 3
Taichung 3
Tampa 3
Taoyuan District 3
Athens 2
Beijing 2
Blackburn 2
Cambridge 2
Cavan 2
Chengdu 2
Chicago 2
Delhi 2
Edina 2
Englewood 2
Goyang-si 2
Ho Chi Minh City 2
Kathmandu 2
Konyaalti 2
Montirone 2
Old Bridge 2
Paris 2
Pune 2
San Diego 2
Shreveport 2
Tokyo 2
Wuhan 2
Atlanta 1
Basking Ridge 1
Brookline 1
Cairo 1
Camden 1
Cheonan 1
Fargo 1
Frankfurt am Main 1
Gangnam-gu 1
Guangzhou 1
Hangzhou 1
Harrisburg 1
Hebei 1
Helsinki 1
Kai Yi Wan 1
Kaohsiung City 1
Lappeenranta 1
Macao 1
Manchester 1
Medford 1
Morgantown 1
Nanjing 1
Nyköping 1
Obata 1
Petaling Jaya 1
Porto 1
Princeton 1
Salt Lake City 1
San Jose 1
Scottsdale 1
Seattle 1
Shiraz 1
Tainan City 1
Uijeongbu-si 1
Waterford 1
Wilmington 1
Woodbridge 1
Wuxi 1
Yongin-si 1
Yongsan-gu 1
Totale 238
Nome #
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy 225
Planet Hunters Tess I: TOI 813, a subgiant hosting a transiting Saturn-sized planet on an 84-day orbit 56
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study 17
Totale 298
Categoria #
all - tutte 676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 676


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/202217 1 0 1 1 2 1 1 4 0 3 1 2
2022/20236 1 0 0 2 0 2 1 0 0 0 0 0
2023/2024218 0 2 12 69 62 63 0 0 0 1 1 8
2024/202546 8 9 6 7 16 0 0 0 0 0 0 0
Totale 298